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INTRODUCTION:  Aggressive  ﬁbromatosis  or Desmoid  ﬁbromatosis  is  a benign  tumor  which  originated
form mesenchymal  tissues  of  the  body.  This tumor  has strong  potential  of  recurrence  and  inﬁltration  but
it does  not  metastasize  to  other  organs  of  the body.  This  case  series  is  focused  to  determine  the  treatment
outcomes  for  pediatric  patients  of aggressive  ﬁbromatosis.
METHODOLOGY:  It  is  a retrospective  case  series  conducted  on  7  patients  presented  to  section  of  Ortho-
pedics,  department  of surgery  of our institute  in  Karachi.  We  included  all  the cases  of  pediatric  patients
from  1 to 16  years,  with  biopsy  proven  ﬁbromatosis  from  January  2000  to  December  2015.
PRESENTATION  OF  CASES:  Out  of 7  pediatric  patients,  there  were  6 (85.7%)  males  and 1 (14.3%)  female
patient.  The  median  age was  6 years  IQR  (5–11)  years.  Gluteal  region  was the  most  common  site of
disease.  Four  patients  (57.1%)  had  positive  tumor  margins  while  three  (42.9%)  had  negative  margins.  Out
of  7 patients,  4 patients  (57.1%)  had  recurrent  disease  and  they had  positive  margins.  The  median  Disease
Free  survival  time  was  14  months  and  there  was  no  expiry  of patients.
CONCLUSION  & RECOMMENDATION:  The  conclusion  of  our study  was  that  aggressive  ﬁbromatosis  is  more
prevalent  in  children  below  15  years  of  age  and  disease  burden  is higher  in male  gender.  Positive  margins
after  surgery  indicate  a high  risk  for  disease  recurrence  therefore;  primary  surgery  with  negative  margins
is the  treatment  of  choice  for children  with  AF.  However,  we  recommend  that  multicenter  trials  should
be conducted  in  the  future  to  clarify  the  role  of  adjuvant  treatment  for patients  with  pediatric  AF.
©  2018  Published  by  Elsevier  Ltd on  behalf  of  IJS  Publishing  Group  Ltd.  This  is  an  open  access  article
under  the  CC  BY  license  (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Desmoid tumor or aggressive ﬁbromatosis (AF) is a benign
tumor of borderline malignant condition, it is inﬁltrative,
deep-seated and muscoloapo neurotic in nature. World health
organization (WHO) deﬁnes ﬁbromatosis as a tumor that originates
from mesenchymal tissues which is non-metastatic but presented
as locally belligerent lesion which accounts for 0.03% of neoplasms
and 3% of every type of soft tissue lesion. Although it is non-
metastasizing tumor but it has high frequency of recurrence [1]. The
incidence rate of AF per year is 0.2–0.4 per 100,000 populations and
there are two peaks of incidence among children falling in age group
of 6 years – 15 years and from age of puberty to 40 years of age in
females. It is a locally destructive tumor that arises from connective
tissue, muscoloaponeurotic and fascial muscle sheath that under-
goes ﬁbroblastic proliferation. AF has a very high predisposition for
local recurrence [2,3].
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In children, the mean age for diagnosis of AF is 8 years with age
range 0–19 years and majority are boys. However, it is observed that
the incidence of AF is much higher in children with positive family
history of aggressive ﬁbromatosis, Gardner’s syndrome and ade-
nomatous polyposis. Children present with slow growing, painless
mass. Although the pathogenesis of these tumors is ambiguous but
an important factor that may  be responsible for its occurrence could
be the deregulation of beta-catenin pathway in which the tumor
suppressor gene is responsible for maintaining the beta-catenin
levels which in turn changes the nuclear signaling and translation
of its pathway [4].
Records of 7 patients were retrieved from January 2000 to
December 2015, presented to section of Orthopedics, department
of surgery of our institute in Karachi. We  included all the pedi-
atric patients ranging 1–6 years, with biopsy proven ﬁbromatosis.
Patients of other border line benign /malignant conditions were
excluded. Since the data of the patients was  retrieved via records
therefore Ethical exemption was  taken from the ethics review com-
mittee of our institute. The aim of this study is to analyze the long
term outcomes of seven cases of pediatric ﬁbromatosis presenting
to a tertiary care hospital in Karachi, Pakistan.
https://doi.org/10.1016/j.ijscr.2018.09.032
2210-2612/© 2018 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).
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Fig. 1. MRI  pelvis of ﬁbromatosis of right gluteal region.
Coronal plane showing mass inﬁltrating in the adjacent gluteus muscles and enter-
ing  in pelvis.
Axial plane showing no lymphadenopathy and normal vessels.
2. Case series
Out of 7 pediatric patients, there were 6 (85.7%) males and 1
(14.3%) female patient. The median age was 6 years IQR (1–16)
years. The most common site of AF was gluteal region, 4 (57.1%),
followed by distal forearm 1(14.3%), axilla 1 (14.3%), knee 1 (14.3%).
All of the patients had a common clinical presentation of swelling
in the lesion affected site for at least 3 months and only 2 patients
had pain symptoms. Patients were advised MRI  and X –ray in radio-
logical imaging. The MRI  pelvis of one of the patient diagnosed with
ﬁbromatosis of right gluteal region showed the mass lesion inﬁl-
trates into the adjacent gluteus muscles and enter into the pelvis
through the sciatic foramen. It is indenting the urinary bladder and
rectum, however the fat planes appear to be preserved. No sig-
niﬁcant pelvic lymphadenopathy noted and the visualized vessels
showed normal ﬂow voids (Fig. 1a & b).
4(57.1%) of the children had positive tumor margins while
3 (42.9%) had negative tumor margins. Recurrence of disease
occurred in 4 (57.1%) patients, while 3 (42.9%) had no recur-
rence (Table 1). Out of the 4 patients that had recurrent disease,
3 patients had recurrence at 28 months, 34 months and 14 months
respectively while one patient had 3 recurrences at 23 months, 35
Table 1
Demographic and clinical characteristics of pediatric ﬁbromatosis patients.
Factors n(%)
Age (years)
Median (IQR) 6 (5-11)
Gender
Male 6 (85.7)
Female 1 (14.3)
Site of tumor
Gluteal region 4 (57.1)
Distal forearm 1 (14.3)
Axilla 1 (14.3)
knee 1 (14.3)
Margin status
Positive 4 (57.1)
Negative 3(42.9)
Recurrence
Yes 4 (57.1)
No 3(42.9)
months and 71 months. The median Disease Free survival time
was 14 months. All patients were alive on last follow up, com-
pleting 15 years of survival; only one patient was lost to follow
up. Moreover, 6 (85.7%) patients received no adjuvant therapy.
Only 1 patient who had multiple recurrence had, received radiation
therapy on the third recurrence in other country. Other patients
with recurrence did not receive any adjuvant therapy because in
our country, the radiation oncologists are not having unanimous
opinion on this. Only negative surgical margins are main treat-
ment plan. All the patients underwent wide margin excision after
preoperative incisional biopsy for diagnosis. Figs. 2 & 3 shows pre-
operative (incisional) biopsy and post-operative excisional biopsy
respectively. The research work has been reported in line with the
PROCESS criteria [5].
3. Discussion
Our study replicated the ﬁndings of several other studies
regarding AF in the pediatric population. The median age of the
participants of study was 6 years which was  consistent with the
ﬁndings from other studies that indicates that ﬁbromatosis can
affect any age group but it is more evident among children. How-
ever, it is reported that about 25% of all AFs occur among children
of less than 15 years of age [6]. The possible explanation of this can
be that the histo-morphology and biological behavior of AFs among
children is more aggressive as compared to adults due to the high
cellularity of the tumor [6].
This study results also indicate that majority of the children who
had aggressive ﬁbromatosis (AF) were boys. Literature also sug-
gest that AF is higher among males [7]. Although there is dearth
of information regarding the biology of AF, but literature sug-
gests that targeting endocrine-mediated proliferation and other
signaling pathways has yielded development of treatments with
some clinical efﬁcacy. It is also observed that anti-estrogen ther-
apy exhibits anti-proliferative activity in such tumors. Hormonal
therapies such as tamoxifen, toremifene, megestrol, progesterone,
testolactone, and goserelin have shown improvement with the
prognosis of such tumors [4]. Hence, the possible explanation of
males been affected by this tumor as shown in our study and lit-
erature may  be due to the involvement of some hormonal factors.
However this needs further to exploration through large scale stud-
ies specially among pediatric population.
Majority of the patients in our study had tumor located in the
gluteal region followed by the extremities. Literature also indi-
cates that majority of these tumors occur at extremities followed
by abdominal, thoracic and rarely in the head and neck [8].
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Fig. 2. Pre-operative (incisional) biopsy.
[A] Low power view of the lesion exhibiting fascicles of spindle cells against ﬁbrotic background. (H&E stain; 100x magniﬁcation) [B] High power view of spindle cells with
bland, elongated and vesicular nuclei. (H&E stain; 400× magniﬁcation) [C] Spindle cells showing patchy expression for alpha smooth muscle actin and [D] patchy nuclear
expression for -Catenin IHC stains. (400× magniﬁcation).
Fig. 3. Post-operative (excisional) biopsy.
[A] Low power view of the lesion exhibiting fascicles of spindle cells against ﬁbrotic background. (H&E stain; 100× magniﬁcation) [B] High power view of spindle cells with
bland,  elongated and vesicular nuclei. (H&E stain; 400× magniﬁcation) [C] Entrapped atrophic skeletal muscle ﬁbers (short arrows) and lymphoid aggregate (large arrow).
(H&E  stain; 200× magniﬁcation) [D] Entrapped adipose tissue (lshort arrow). (H&E stain; 200× magniﬁcation).
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Additionally, our study results also suggested that after surgery
a high number of individuals had positive tumor margin and all of
them had recurrence of disease. A study indicated a higher propor-
tion of children who had positive margins after primary surgery
developed disease recurrences versus those with negative margins
[7]. Therefore, the high risk of disease recurrence among patients
with positive margins indicates that there is a need of exploration
of the role of the adjuvant treatment in such patients. A study con-
ducted in Netherland on a sample of 13 children suggested that
younger children (0–18 years) who received radiotherapy showed
less locoregional control of disease however, when the dose was
increased above 55 Gy, there was an improvement in the outcome
but on the contrary the complications were increased. On the con-
trary in our country, the concept of adjuvant treatment is still
ambiguous and post radiation therapy complications could be a
reason. Moreover, studies also suggest that the recurrence rate in
children varies from 23%–83% which results in multiple resections.
Furthermore, studies also suggests that negative surgical margins
causes decrease in the recurrence of AF [4,7,8].
The overall survival status of our study patients is 100% at 15
years, there is no death reported for the patients who  were on fol-
low up and this survival pattern is comparable to the survival status
reported in literature [8]. All of the patients in our study were in
regular follow up with us.
Patients in our study had recurrence and majority of the patients
had not received any adjuvant therapy except one patient who
had multiple recurrences. Literature suggests that adjuvant therapy
must be considered for patients with residual disease and among
those who have recurrent, progressive, or unresectable tumor.
Traditional cytotoxic and non-cytotoxic agents are the chemother-
apeutic therapy of choice [9]. However, there is still a need of
multicenter, prospective (randomized) trials to clarify the role of
adjuvant treatment for patients with pediatric AF [3].
4. Conclusions and recommendations
The conclusion of our study is that AF is commonly found among
children below 15 years of age, affecting males more as compared to
females. Positive margins after surgery indicate a high risk for dis-
ease recurrence therefore; primary surgery with negative margins
is the treatment choice for children with AF. However, radiation
may  assist in maintaining local control of these tumors in patients
with positive margins or residual disease therefore use of adjuvant
therapy in children with AF may  be a reasonable alternative. How-
ever, multicenter prospective (randomized) trials will be necessary
to clarify the role of adjuvant treatment for patients with pediatric
AF.
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